Nuvation Bio (NUVB) Competitors $1.94 -0.02 (-1.02%) Closing price 03:58 PM EasternExtended Trading$1.93 -0.01 (-0.52%) As of 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NUVB vs. RXRX, XENE, AMRX, CPRX, HCM, BHC, NAMS, TWST, EWTX, and IBRXShould you be buying Nuvation Bio stock or one of its competitors? The main competitors of Nuvation Bio include Recursion Pharmaceuticals (RXRX), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), HUTCHMED (HCM), Bausch Health Companies (BHC), NewAmsterdam Pharma (NAMS), Twist Bioscience (TWST), Edgewise Therapeutics (EWTX), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry. Nuvation Bio vs. Recursion Pharmaceuticals Xenon Pharmaceuticals Amneal Pharmaceuticals Catalyst Pharmaceuticals HUTCHMED Bausch Health Companies NewAmsterdam Pharma Twist Bioscience Edgewise Therapeutics ImmunityBio Recursion Pharmaceuticals (NASDAQ:RXRX) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, community ranking, analyst recommendations and institutional ownership. Do insiders & institutionals believe in RXRX or NUVB? 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 15.8% of Recursion Pharmaceuticals shares are owned by company insiders. Comparatively, 5.1% of Nuvation Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts prefer RXRX or NUVB? Recursion Pharmaceuticals currently has a consensus price target of $8.25, indicating a potential upside of 26.34%. Nuvation Bio has a consensus price target of $8.33, indicating a potential upside of 329.55%. Given Nuvation Bio's stronger consensus rating and higher probable upside, analysts plainly believe Nuvation Bio is more favorable than Recursion Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Recursion Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Does the MarketBeat Community prefer RXRX or NUVB? Nuvation Bio received 23 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 81.54% of users gave Nuvation Bio an outperform vote while only 55.56% of users gave Recursion Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRecursion PharmaceuticalsOutperform Votes3055.56% Underperform Votes2444.44% Nuvation BioOutperform Votes5381.54% Underperform Votes1218.46% Does the media refer more to RXRX or NUVB? In the previous week, Recursion Pharmaceuticals had 1 more articles in the media than Nuvation Bio. MarketBeat recorded 6 mentions for Recursion Pharmaceuticals and 5 mentions for Nuvation Bio. Recursion Pharmaceuticals' average media sentiment score of 0.84 beat Nuvation Bio's score of 0.67 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvation Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is RXRX or NUVB more profitable? Nuvation Bio has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -579.52%. Nuvation Bio's return on equity of -21.89% beat Recursion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Recursion Pharmaceuticals-579.52% -76.56% -55.68% Nuvation Bio N/A -21.89%-17.86% Which has more risk & volatility, RXRX or NUVB? Recursion Pharmaceuticals has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Which has preferable valuation & earnings, RXRX or NUVB? Nuvation Bio has lower revenue, but higher earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRecursion Pharmaceuticals$58.49M44.88-$328.07M-$1.66-3.93Nuvation Bio$7.87M83.45-$75.80M-$2.26-0.86 SummaryNuvation Bio beats Recursion Pharmaceuticals on 13 of the 19 factors compared between the two stocks. Remove Ads Get Nuvation Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for NUVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NUVB vs. The Competition Export to ExcelMetricNuvation BioPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$657.04M$6.99B$5.68B$19.75BDividend YieldN/A2.72%4.55%3.75%P/E Ratio-0.897.2324.5534.05Price / Sales83.45230.77395.7228.57Price / CashN/A65.6738.1617.54Price / Book0.706.617.064.63Net Income-$75.80M$142.13M$3.19B$1.02B7 Day Performance-1.27%2.79%1.49%1.12%1 Month Performance-5.13%2.70%5.87%-1.07%1 Year Performance-13.97%-4.42%14.94%7.08% Nuvation Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NUVBNuvation Bio2.5619 of 5 stars$1.94-1.0%$8.33+329.6%-15.4%$657.04M$7.87M-0.8960RXRXRecursion Pharmaceuticals2.2051 of 5 stars$6.84+7.7%$8.25+20.6%-35.3%$2.75B$58.49M-4.47400XENEXenon Pharmaceuticals2.4861 of 5 stars$35.60+0.8%$57.38+61.2%-17.2%$2.72B$9.43M-12.62210AMRXAmneal Pharmaceuticals3.4702 of 5 stars$8.62-1.5%$10.80+25.3%+46.5%$2.67B$2.79B-12.687,700Positive NewsCPRXCatalyst Pharmaceuticals4.8603 of 5 stars$21.81+3.8%$32.50+49.0%+63.6%$2.65B$491.73M18.4880Analyst RevisionHCMHUTCHMED2.5643 of 5 stars$15.14-3.5%$19.00+25.5%-7.9%$2.64B$610.81M0.001,988Gap DownBHCBausch Health Companies3.4444 of 5 stars$7.06-1.3%$7.42+5.1%-24.0%$2.60B$9.63B-58.7920,270NAMSNewAmsterdam Pharma2.6471 of 5 stars$23.34-0.1%$43.33+85.7%+7.8%$2.56B$45.56M-8.984High Trading VolumeTWSTTwist Bioscience2.9695 of 5 stars$42.34+6.0%$54.40+28.5%+29.9%$2.53B$330.19M-12.53990News CoverageEWTXEdgewise Therapeutics1.7849 of 5 stars$26.43+3.0%$45.38+71.7%+43.8%$2.52BN/A-17.6260Gap DownIBRXImmunityBio2.2442 of 5 stars$2.91+1.4%$12.19+318.8%-53.0%$2.48B$14.75M-3.16590Positive News Remove Ads Related Companies and Tools Related Companies Recursion Pharmaceuticals Alternatives Xenon Pharmaceuticals Alternatives Amneal Pharmaceuticals Alternatives Catalyst Pharmaceuticals Alternatives HUTCHMED Alternatives Bausch Health Companies Alternatives NewAmsterdam Pharma Alternatives Twist Bioscience Alternatives Edgewise Therapeutics Alternatives ImmunityBio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NUVB) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvation Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvation Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NUVB Stock Free NUVB Stock Alerts